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FILLING IN THE CRACKS:
IMPROVING THE REGULATION
OF DIRECT-TO-CONSUMER
GENETIC TESTS
SERRA J. SCHLANGER
Advances in genetic technology and the increased acceptance of
genetic testing by the general public have led to the development and sale
of direct-to-consumer (DTC) genetic tests.1 Genetic testing is one of the
fastest growing areas of laboratory testing.2 A recent survey found more
than thirty different DTC genetic testing companies offering genetic tests
for both health and non-health related purposes.3 These tests range in cost
from $78 to $68,500.4 The DTC genetic testing companies advertise that an

Copyright © 2011 by Serra J. Schlanger.
 J.D. Candidate, 2011, University of Maryland School of Law (Baltimore, MD); B.A., 2005,
Science, Technology, and Society, Vassar College (Poughkeepsie, NY). The author wishes to
thank Professor Leslie Meltzer Henry for her guidance in developing this Comment and the
editorial staff of the Journal of Health Care Law & Policy. She would also like to thank Saul
Ehrenpreis and her family for their encouragement and support.
1. Andrew S. Robertson, Taking Responsibility: Regulations and Protections in Direct-toConsumer Genetic Testing, 24 BERKELEY TECH. L.J. 213, 214–15 (2009).
2. See BIN CHEN ET AL., DEP‟T OF HEALTH & HUMAN SERVS., CTRS. FOR DISEASE
CONTROL & PREVENTION, GOOD LABORATORY PRACTICES FOR MOLECULAR GENETIC TESTING
FOR HERITABLE DISEASES AND CONDITIONS, 58 MORBIDITY & MORTALITY WKLY. REP. 3
(2009)
[hereinafter
LABORATORY
PRACTICES],
available
at
http://www.cdc.gov/mmwr/PDF/rr/rr5806.pdf (describing the rapid growth in the number of
available genetic tests and the number of laboratories performing genetic testing).
3. See GENETICS & PUB. POL‟Y CTR., DTC GENETIC TESTING COMPANIES (Feb. 26, 2010)
[hereinafter
DTC
GENETIC
TESTING
COMPANIES],
available
at
http://www.dnapolicy.org/news.release.php?action=detail&pressrelease_id=137 (compiling a list
of DTC genetic testing companies and information on what tests each company offers).
4. See e.g., Low Cost At Home DNA Paternity Test, HOMEDNA, https://www.homedna.com
(last visited Mar. 1, 2011) (advertising a $78 DNA Home Paternity Testing System); Ryan
McBride, Knome Challenged to Keep in Step With Falling Genetic Sequencing Prices,
XCONOMY, Jan. 1, 2010, http://www.xconomy.com/boston/2010/01/20/knome-challenged-tokeep-in-step-with-falling-genetic-sequencing-prices/?single_page=true
(detailing
Knome‟s
complete genetic sequence service price decrease from $350,000 in 2008 to the current price of
$68,500).
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individual‟s genetic profile can be used to find love,5 to fill in a family
tree,6 to determine genetic athletic advantages,7 to assist in weight loss,8
and to discover individual genetic risk for forty-seven different diseases and
traits.9 Although more than 1,200 genetic tests, covering a wide variety of
issues and conditions, are currently available on the consumer market, the
Food and Drug Administration (FDA) has approved fewer than a dozen of
them.10
DTC genetic tests currently fall through the regulatory cracks because
several governmental agencies oversee individual aspects and components
of genetic testing, but no single agency covers all genetic tests.11 This
apparent lack of cohesive regulation is startling because the general public
widely believes that the government comprehensively regulates genetic
testing.12 Unaware of the minimal regulation and oversight, consumers may
have misplaced confidence in the claims made by those selling genetic tests
and may be unaware that a particular genetic test may not provide
meaningful results or be based on accurate science.13 The absence of a
comprehensive regulatory scheme has created an opportune environment
for genetic test makers to directly target consumers and to encourage the
purchase of genetic tests with unproven medical value.14 The current
limited regulatory structure legally fails to protect the rights and interests of
vulnerable individuals.15

5. GENEPARTNER.COM, http://www.genepartner.com (last visited Mar. 1, 2011).
6. Discover DNA Ancestry and Genetic History with our DNA Test, 23ANDME,
https://www.23andme.com/ancestry/ (last visited Mar. 1, 2011).
7. ATLAS FIRST SPORTGENE TEST, http://www.atlasgene.com (last visited Mar. 1, 2011).
8. INHERENT HEALTH, WEIGHT MANAGEMENT, http://www.inherenthealth.com/ourtests/weight-management.aspx (last visited Mar. 1, 2011).
9. DECODEME, http://www.decodeme.com (last visited Mar. 1, 2011).
10. Joan L. McGregor, Why John Stuart Mill Would Support Restriction on DTC Marketing
of Genetic Tests, 8 AM. J. BIOETHICS 9, 9 (2008).
11. Rebecca Antar Novick, Note, One Step at a Time: Ethical Barriers to Home Genetic
Testing and Why the U.S. Health Care System Is Not Ready, 11 N.Y.U. J. LEGIS. & PUB. POL‟Y
621, 624 (2008).
12. Consumer-Directed Promotion of Regulated Medical Products: Public Hearing Docket
No. 2005N-0354 (2005) (comments of Gail Javitt, Genetics and Public Policy Center), available
at http://www.dnapolicy.org/resources/FDA_Testimony.pdf.
13. U.S. GOV‟T ACCOUNTABILITY OFFICE, GAO-06-977T, NUTRIGENETIC TESTING TESTS
PURCHASED FROM FOUR WEB SITES MISLEAD CONSUMERS, 2 (2006) (prepared statement of
Gregory Kutz, Managing Director of Forensic Audits and Special Investigations for At Home
DNA Tests: Marketing Scam or Medical Breakthrough: Hearing Before the S. Special Comm. on
Aging, 109th Cong. (2006)); Gail H. Javitt & Kathy Hudson, Federal Neglect: Regulation of
Genetic Testing, 22 ISSUES SCI. & TECH. 59, 62 (2006), available at
http://www.dnapolicy.org/resources/Issues_in_Science_and_Technology.pdf.
14. Javitt & Hudson, supra note 13, at 62.
15. Sjef Gevers, The Marketing of Health Products, With Special Reference to Do-It-Yourself
Tests, 22 MED. & L. 199, 206 (2003).
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Part I of this Comment explains the unique nature of genetic material
and the concerns that arise when individuals undergo genetic testing. These
concerns focus on test result accuracy, the influence of genetic information
on medical practice, adequate genetic counseling, and the psychological
impact of genetic information.16 Part I also introduces the current state of
clinical and DTC genetic test regulation and examines the different
regulatory approaches taken by individual states.17 Part I identifies the
FDA, the Federal Trade Commission (FTC), and the Centers for Medicare
and Medicaid Services (CMS) as the three federal agencies that have the
greatest potential to regulate DTC genetic tests and assesses the agencies‟
current regulations.18
The FDA has previously considered and managed similar concerns
about test result accuracy, adequate result counseling, and the psychological
impact of test results during the development of the HIV home test kit.19
Part II of this Comment examines the contentious development of the HIV
home test kit and focuses on the arguments about home test kit accuracy
and the availability of pre- and post-test counseling for home test kit
users.20 Part II also describes the HIV home test kit that received FDA
approval in 1996.21
Part III of this Comment looks forward to potential new developments
and solutions for the current patchwork system of DTC genetic test
regulation. Part III suggests that the FDA should look to the HIV home test
kit counseling requirement as a model to help combat current concerns
about the impact of DTC genetic tests on individual health decision
making.22 Part III also recommends that the FTC and CMS increase their
efforts to protect consumers from false and misleading advertisements for
DTC genetic tests.23 Although this Comment focuses on DTC genetic test

16. See Robert M. Cook-Deegan, NIH-DOE Joint Working Group on Ethical, Legal, and
Social Issues Established, HUMAN GENOME NEWS (Human Genome Program, U.S. Dep‟t of
Energy,
Washington,
D.C.),
May
1990,
available
at
http://www.ornl.gov/sci/techresources/Human_Genome/publicat/hgn/v2n1/05elsi.shtml
(identifying nine topics and issues that may arise with genome technology development); Human
Genome Project, Ethical, Legal, and Social Issues – Genome Research, U.S. DEP‟T OF ENERGY
OFFICE OF SCI., http://www.ornl.gov/sci/techresources/Human_Genome/elsi/elsi.shtml (last
visited Mar. 1, 2011) (raising questions related to societal concerns about the availability genetic
information).
17. See infra Part I.A.
18. See infra Part I.B.
19. Ronald Bayer et al., Testing for HIV Infection at Home, 332 NEW ENG. J. MED. 1296
(1995).
20. See infra Part II.A.
21. See infra Part II.B.
22. See infra Part III.A.
23. See infra Parts III.B–C.
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regulation, the proposed regulatory improvements may also impact and
improve the quality of physician-provided genetic tests and can help
provide patients and physicians with greater confidence in all genetic
testing.24
I. CURRENT CONCERNS AND THE STATE OF REGULATION
Genetics is the science of biological variation and includes the science
and practice of diagnosis, prevention, and management of genetic
disorders.25 Since the double helix structure of DNA was first described in
1953,26 modern genetic research has expanded as the scientific and medical
communities try to gain a better understanding of the genes that control
human inherited traits.27 Currently a wide variety of genetic tests can
provide information for more than 1,500 diseases.28
A genetic test is defined as “[t]he analysis of human DNA, RNA,
chromosomes, proteins, and certain metabolites in order to detect inherited
disease-related genotypes, mutations, phenotypes, or karyotypes for clinical
purposes.”29 Such clinical purposes include identifying carriers of genetic
diseases, prenatal and post-birth testing for disease-causing genetic
abnormalities, predicting an individual‟s risk of disease development,
predicting an individual‟s response to specific medications, and establishing

24. Javitt & Hudson, supra note 13, at 66.
25. Mary B. Mahowald, Genetic Technologies and Their Implications for Women, 3 U. CHI.
L. SCH. ROUNDTABLE 439, 440 (1996).
26. James D. Watson & Francis H.C. Crick, A Structure for Deoxyribose Nucleic Acid, 171
NATURE 737, 737 (1953). In addition to describing the structure of DNA, the authors also note
that the structure “immediately suggests a possible copying mechanism for the genetic material.”
Id.
27. See generally James D. Watson & Francis H.C. Crick, Genetical Implications of the
Structure of Deoxyribonucleic Acid, 171 NATURE 964, 966 (1953) (explaining Watson and
Crick‟s original hypothesis about how the structure of DNA provides a template for genetic
inheritance).
28. Daniel Schlein, New Frontiers for Genetic Privacy Law: The Genetic Information
Nondiscrimination Act of 2008, 19 GEO. MASON U. CIV. RTS. L.J. 311, 311 (2009).
29. PROMOTING SAFE AND EFFECTIVE GENETIC TESTING IN THE UNITED STATES: FINAL
REPORT OF THE TASK FORCE ON GENETIC TESTING, 6 (Neil A. Holtzman & Michael S. Watson
eds., 1998) [hereinafter FINAL REPORT], available at http://www.genome.gov/10001733.
Genotype refers to an individual‟s collection of genes. Talking Glossary of Genetic Terms, NAT‟L
HUMAN GENOME RESEARCH INST., http://www.genome.gov/glossary/index.cfm (last visited Mar.
1, 2011) [hereinafter Glossary]. One half of an individual‟s genes are inherited from the mother;
the other half is inherited from the individual‟s father. FINAL REPORT, supra note 29, at 178. A
mutation is a change in an individual‟s DNA sequence that may be caused by DNA copying
mistakes, exposure to radiation or chemicals, or infection by viruses. Glossary, supra note 29.
Phenotype refers to an individual‟s observable traits and characteristics that result from the
interaction of the genotype with the environment. Id.; FINAL REPORT, supra note 29, at 179.
Karyotype refers to an individual‟s collection of chromosomes or a laboratory technique used to
look for abnormal chromosome numbers or structure. Glossary, supra note 29.
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an individual‟s clinical diagnosis or prognosis.30 At first, genetic testing
was only offered and available through health care providers,31 so genetic
testing companies marketed their services to the providers.32 However, by
2002, as the potential market for genetic testing became more apparent,
companies began to market their genetic tests directly to consumers.33 Early
advertisements used themes of fear, hope, and peace of mind to encourage
women and certain ethnic groups to request genetic testing from their
physicians.34 These advertisement themes continue to be used today in an
expanded genetic testing market that now encompasses more individuals
and a wider variety of conditions.35
Today, the majority of genetic tests are still only available in health
care settings; however, some companies have made genetic tests available
directly to consumers, primarily though the Internet.36 The Internet
currently hosts more than thirty different DTC genetic testing companies
that offer a wide variety of genetic testing services.37 These tests are
advertised for both medical and non-medical purposes and can be grouped
into four broad categories: 1) individual susceptibility to disease, 2)
nutritional and metabolic assessments, 3) genetic linkage to individual traits
or characteristics, and 4) ancestry information.38

30. FINAL REPORT, supra note 29, at 6; Gail H. Javitt et al., Direct-to-Consumer Genetic
Tests, Government Oversight, and the First Amendment: What the Government Can (and Can’t)
Do to Protect the Public’s Health, 57 OKLA. L. REV. 251, 257 (2004). A carrier is a person who
has inherited a disease-causing gene from one parent and a normal gene from the other parent.
FINAL REPORT, supra note 29, at 177. Generally a carrier suffers no ill effects of the diseasecausing gene. Id.
31. Cynthia Marietta & Amy L. McGuire, Direct-to-Consumer Genetic Testing: Is It the
Practice of Medicine?, 37 J.L. MED. & ETHICS 369, 369 (2009).
32. See Javitt et al., supra note 30, at 262 (“The major laboratories generally sell their testing
services to health care providers and hospitals, not directly to consumers.”).
33. See Sarah E. Gollust et al., Limitations of Direct-to-Consumer Advertising for Clinical
Genetic Testing, 288 JAMA 1762, 1762 (2002) (recounting some of the advertisements for genetic
tests and services that appeared in the popular press). As early as 2001, advertisements for breast
cancer genetic testing appeared in Broadway show programs and on television. Ellen Matloff &
Arthur Caplan, Direct to Confusion: Lessons Learned from Marketing BRCA Testing, 8 AM. J.
BIOETHICS 5, 6 (2008).
34. Gollust et al., supra note 33, at 1762–63.
35. See Matloff & Caplan, supra note 33, at 6–7 (discussing Myriad Genetics DTC “public
awareness campaign”); McGregor, supra note 10, at 9 (reporting the “amazing array of issues”
covered by DTC genetic tests).
36. Javitt et al., supra note 30, at 262.
37. DTC GENETIC TESTING COMPANIES, supra note 3.
38. Marietta & McGuire, supra note 31, at 369. The second and fourth categories, nutritional
and metabolic assessments and ancestry information, generally fall outside the use of genetic
testing for medical purposes. Other non-medical uses of genetic tests include paternity and sibling
testing. This Comment will primarily address issues related to the use of genetic testing for
medical purposes.
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Virtually all information about an individual‟s health and physical
well-being can be considered genetic information because DNA underlies
almost every aspect of human health.39 However, genetic information is
fundamentally different from other forms of health information, and genetic
testing differs from other diagnostic tests and medical treatments.40 Genetic
test results are often used primarily for predictive purposes even though the
probability that an individual will develop a condition in the future is
uncertain.41 A negative test result only indicates the absence of a particular
gene sequence that is linked to a disease or condition, so negative test
results do not always rule out the possibility of future disease occurrence.42
Similarly, positive test results do not necessarily mean that an individual
will develop a disease or condition because the positive result merely
indicates the presence of a particular gene sequence that is associated with
the occurrence of a disease or condition.43 Even in circumstances where an
individual‟s positive test result directly correlates to future disease
development, the positive test result does not indicate when or how the
disease will develop, or the severity of the disease manifestation.44
Furthermore, genetic test results may have limited use because there are
currently few interventions available to improve the outcome of most
genetically linked diseases.45
Although genetic information is unique to each individual, it is also
inherently familial because genes are the basis of hereditary traits that pass
from one generation to the next.46 Genetic testing inevitably uncovers
information about an individual‟s genetic relatives,47 which may force those
who undergo these tests to confront complex questions about the disclosure

39. OFFICE OF SCI., U.S. DEP‟T OF ENERGY, DOE/SC-0083, GENOMICS AND ITS IMPACT ON
SCIENCE
AND
SOCIETY,
5
(2008),
available
at
http://www.ornl.gov/sci/techresources/Human_Genome/publicat/primer2001/primer11.pdf; Ellen
Wright Clayton, Ethical, Legal, and Social Implications of Genomic Medicine, 349 NEW. ENG. J.
MED. 562, 562 (2003).
40. Javitt et al., supra note 30, at 260.
41. Katherine Wasson, Consumer Alert: Ethical Issues Raised By the Sale of Genetic Tests
Directly to Consumers, 8 AM. J. BIOETHICS 16, 17 (2008).
42. FINAL REPORT, supra note 29, at 3; Jennifer A. Gniady, Note, Regulating Direct-toConsumer Genetic Testing: Protecting the Consumer Without Quashing a Medical Revolution, 76
FORDHAM L. REV. 2429, 2435 (2008).
43. FINAL REPORT, supra note 29, at 3; Javitt et al., supra note 30, at 260.
44. Javitt et al., supra note 30, at 260–61.
45. FINAL REPORT, supra note 29, at 2–3; Gniady, supra note 42, at 2435.
46. See Javitt et al., supra note 30, at 261 (describing how related individuals may be carriers
for genetic traits).
47. Patricia Roche, Caveat Venditor: Protecting Privacy and Ownership Interests in DNA, in
HUMAN DNA: LAW AND POLICY INTERNATIONAL AND COMPARATIVE PERSPECTIVES 33, 34
(Bartha M. Knoppers ed., 1997).
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of test results to their relatives.48 In addition, individuals may be pressured
by genetic relatives to undergo testing that they would not otherwise
consider.49
Though genetic test results may not be more informative than other
traditional forms of health information, the general public and media often
perceive genetic information as infallible.50 Individuals who undergo
genetic testing have a risk of receiving false positive or false negative
results, which may lead them to make potentially harmful choices based on
false information.51 Despite the predictive quality of genetic testing,
individuals often interpret their results as a view of their medical destiny.52
In addition genetic information has “historically been used as the basis for
categorizing members of society” and may still be used for purposes of
discrimination.53
Concerns about the unique nature of genetic information and genetic
testing can be generally categorized as relating to: result accuracy and the
influence of genetic information on medical practice; adequate genetic
counseling and the psychological impact of genetic information; personal
privacy, confidentiality, and fair use of genetic information; and the
commercialization of genetic products.54 In the 1990s, an official Task
Force on Genetic Testing55 raised concerns that certain genetic tests were
made available to patients before the tests were determined “to be safe,
effective, and useful.”56 Today, many health care providers echo these
concerns and worry that the genetic tests marketed directly to consumers
are not as accurate, valid, or reliable as tests provided in a clinical setting.57
Despite concerns about test result accuracy, “DTC genetic tests are
becoming more widely utilized [by consumers] due to their convenience
48. Id.; Javitt et al., supra note 30, at 261.
49. Gevers, supra note 15, at 202.
50. Javitt et al., supra note 30, at 261.
51. Wasson, supra note 41, at 17. “A false positive test indicates a person has X when he does
not and false negative tests indicates a person is free of X when he actually has it.” Id.
52. Clayton, supra note 39, at 563. See also Is your DNA your destiny?, NAVIGENICS,
http://www.navigenics.com/visitor/genetics_and_health/dna_basics/is_dna_destiny/ (last visited
Mar. 1, 2011).
53. Roche, supra note 47, at 34.
54. Cook-Deegan, supra note 16. These concerns were first identified by a joint working
group established by the National Institutes of Health (NIH) and the Department of Energy (DOE)
to address policy issues in response to the accelerating pace of scientific development and
genomic technology following the completion of the Human Genome Project. Id.
55. The Task Force on Genetic Testing was an official government advisory group created by
the NIH-DOE working group and charged with the task of making recommendations to assure the
public that genetic tests are safe and effective. FINAL REPORT, supra note 29, at 4.
56. Id. at xii; Gregorio M. Garcia, The FDA and Regulation of Genetic Tests: Building
Confidence and Promoting Safety, 48 JURIMETRICS J. 217, 219 (2008).
57. Wasson, supra note 41 at 17.
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and confidential nature.”58 Individual consumers worried about the
wrongful disclosure of their genetic information may choose to use DTC
genetic tests because the results are reported directly to their homes.59
Though few cases of discrimination based on an individual‟s genetic
information have been reported, many consumers and patients are wary of
the potential for such misuse.60 Avoiding the traditional clinical setting
prevents genetic test results from being included in an individual‟s medical
records and increases that individual‟s protection from the potential
disclosure of genetic test results to employers or insurance companies.61
The lack of physician involvement in DTC genetic testing is
troublesome to many health care professionals who worry that individuals
who receive their genetic test results will not understand the complex nature
of these results.62 Patients who undergo clinical genetic testing traditionally
receive genetic counseling from their health care provider who can explain
the probabilistic nature of genetic test results.63 Without any counseling,
individuals may be confused by their results because the absence of a
particular gene does not ensure that the individual will not develop a
particular disease.64 Absent genetic counseling, individuals may also face
unnecessary stress about their results because the presence of a particular
gene does not guarantee that the individual will develop a particular
condition.65 There is evidence that even when individuals receive
counseling, “[patients] are unable to understand the explanations of test
results and lack an understanding of both the risks of developing specific
58. Lauren Solberg, Note, Over the Counter but Under the Radar: Direct-to-Consumer
Genetics Tests and FDA Regulation of Medical Devices, 11 VAND. J. ENT. & TECH. L. 711, 714–
15 (2009).
59. Wasson, supra note 41, at 18.
60. Schlein, supra note 28, at 315.
61. Wasson, supra note 41, at 18. The disclosure of an individual‟s personal health
information, including genetic test results, by a health care provider is regulated by the Health
Insurance Portability and Accountability Act of 1996 (HIPAA). Health Insurance Portability and
Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat. 1936 (1996) (codified in scattered
sections of 26, 29, & 42 U.S.C.). The use of genetic information by employers and insurance
companies is limited by the Genetic Information Nondiscrimination Act (GINA). Genetic
Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 881 (2008) (to be
codified in scattered sections of 26, 29, & 42 U.S.C.). GINA prohibits group health plans from
adjusting premium or contribution amounts on the basis of genetic information. §§ 101–106, 122
Stat. at 883–905. GINA also prohibits employers from using genetic information to make
decisions regarding hiring, firing, job placement and promotions in addition to regulating how
employers may acquire an employee‟s genetic information. §§ 201–213, 122 Stat. at 905–920.
62. Audrey Chapman, DTC Marketing of Genetic Tests: The Perfect Storm, 8 AM. J.
BIOETHICS 10, 10 (2008); Wasson, supra note 41, at 17–18.
63. See Novick, supra note 11, at 635–36 (describing the discussions genetic counselors have
with patients deciding to undergo genetic testing).
64. FINAL REPORT, supra note 29, at 3.
65. Id.
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diseases and the role that the environmental factors play.”66 A genetic
predisposition to a condition does not indicate how severe the symptoms
will be, or how the individual will respond to available treatments.67
Opponents of DTC tests assert that individuals who utilize these tests are
particularly likely to face adverse effects “when the interpretation of test
results requires specific expertise, [when] the outcome of the test results in
options that require expert advice, and [when] the potential psychological
impact makes professional support necessary.”68 Additionally, opponents
argue that consumers need counseling to understand their genetic test
results and to best utilize the results when making important health care
decisions based on those results.69 Supporters of DTC genetic testing argue
that many physicians are insufficiently prepared to interpret genetic test
results,70 and that individuals have a right to access their own genetic
information.71 The increased use of genetic tests and the emergence of DTC
genetic tests have stimulated further debate about the regulation of genetic
tests.72
A. State Regulation
In 2007 and 2008 New York and California sent “cease and desist”
letters to thirty-one genetic testing companies that engage in DTC sales.73
The letters targeted companies that provide genetic tests directly to
consumers without the involvement of a licensed physician74 and stated that
the companies “need licenses to solicit specimens of DNA from state
residents.”75 Following these letters, California granted licenses to a limited
number of these companies.76 California and New York are among the

66. Gniady, supra note 42, at 2448.
67. Id. at 2435.
68. Gevers, supra note 15, at 202.
69. Wasson, supra note 41, at 17. For example, a woman who has a genetic test result that
indicates a predisposition to the development of breast cancer may choose to undergo prophylactic
breast surgery in order to reduce her risk of disease development.
70. Gniady, supra note 42, at 2448.
71. Wasson, supra note 41, at 17.
72. See generally At Home DNA Tests: Marketing Scam or Medical Breakthrough: Hearing
Before the S. Special Comm. on Aging, 109th Cong. 1–2 (2006) (statement of Sen. Gordon H.
Smith, Chairman, S. Special Comm. on Aging) (describing concerns regarding the oversight of
and science behind DTC genetic tests).
73. Jane E. Brody, Buyer Beware of Home DNA Tests, N.Y. TIMES, Sept. 1, 2009,
http://www.nytimes.com/2009/09/01/health/01brod.html?_r=1&nl=health&emc=healthupdateemb
3#; Andrew Pollack, Gene Testing Questioned by Regulators, N.Y. TIMES, June 26, 2008,
http://www.nytimes.com/2008/06/26/business/26gene.html?_r=1.
74. Robertson, supra note 1, at 213.
75. Brody, supra note 73.
76. Robertson, supra note 1, at 213.
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twelve states that currently allow limited DTC testing.77 While some states
limit the use of DTC testing by focusing on specific tests that may be
ordered directly by consumers,78 other states limit the use of DTC tests to
those tests ordered by licensed practitioners, physicians, or authorized
professionals listed in the statute and further require that results only be
reported to the authorized person who requested the test.79
Twenty-five states and the District of Columbia allow DTC testing
without any restriction,80 while thirteen states prohibit all DTC testing.81
Many states that prohibit all DTC testing specify that the ordering of tests is
limited to licensed physicians or other professionals authorized by law to
make medical diagnoses.82 The majority of states that allow unrestricted
DTC testing have no applicable state statute or regulation that addresses
these tests,83 which effectively allows DTC testing to occur in the state.84
Only five states that allow unrestricted DTC testing and the District of
Columbia have laws that may be interpreted to apply to DTC testing.85
These laws generally do not address DTC testing directly, but instead focus
on the need for informed consent86 or the need for a physician to receive
and interpret the results.87 Although state restrictions that require a
physician order the test and receive the test results seem to indicate a level
of validity in the testing process, DTC genetic testing companies that wish
77. GENETICS & PUB. POL‟Y CTR., SURVEY OF DIRECT-TO-CONSUMER TESTING STATUTES
REGULATIONS (June 2007) [hereinafter DTC STATUTE SURVEY], available at
http://www.dnapolicy.org/resources/DTCStateLawChart.pdf. The other states that allow limited
DTC testing are: Arizona, Colorado, Florida, Illinois, Maine, Maryland, Massachusetts, Nevada,
New Jersey, and Oregon. Id.
78. E.g., ME. REV. STAT. ANN. tit. 22, § 2030 (2004); NEV. REV. STAT. ANN. § 652.190
(2008).
79. E.g., ARIZ. REV. STAT. ANN. § 36-470 (2009); CAL. HEALTH & SAFETY CODE § 123148
(2006); FLA. STAT. ANN. §§ 483.181(1)–(2) (2006 & Supp. 2011); 210 ILL. COMP. STAT. 25/7-101
to -102 (2008).
80. DTC STATUTE SURVEY, supra note 77. The states that allow DTC testing without
restriction include: Alaska, Arkansas, Delaware, Indiana, Iowa, Kansas, Louisiana, Minnesota,
Mississippi, Missouri, Montana, Nebraska, New Mexico, North Carolina, North Dakota, Ohio,
Oklahoma, South Dakota, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and
Wisconsin. Id.
81. Id. The states that prohibit all DTC testing include: Alabama, Connecticut, Georgia,
Hawaii, Idaho, Kentucky, Michigan, New Hampshire, Pennsylvania, Rhode Island, South
Carolina, Tennessee, and Wyoming. Id.
82. E.g., GA. CODE ANN. § 31-22-4(a) (2009); TENN. CODE ANN. § 68-29-121 (2006 & Supp.
2010).
83. DTC STATUTE SURVEY, supra note 77. Twenty of the twenty-five states that allow DTC
testing have state laws that are “silent on the issue.” Id.
84. Robertson, supra note 1, at 224.
85. DTC STATUTE SURVEY, supra note 77. Nebraska, North Carolina, Virginia, Washington,
and Wisconsin have state laws that may be interpreted to apply to DTC testing. Id.
86. E.g., NEB. REV. STAT. § 71-551 (2009).
87. E.g., WASH. ADMIN. CODE § 246-338-070 (2009).
AND
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to circumvent these requirements often have “an arrangement with a
physician whose name is used to order tests and report results to the
consumer.”88 However, affiliation with a physician does not necessarily
indicate that the test is accurate or that the patient receives counseling about
the test results.89 Similarly, having a doctor working under a contract with
the company review the consumer‟s test orders before the specimens are
given to the testing laboratory is not the same as having the individual‟s
physician order the tests.90
In addition to regulating the provision of DTC genetic tests, states can
also use their unfair or deceptive trade practice statutes to protect
consumers.91 Although every state has enacted laws to generally regulate
false advertising and deceptive marketing practices,92 none of the states
have laws that directly address the advertising or marketing of genetic
testing.93 Instead, many of the states‟ broad statutes prohibit deceptive trade
practices that may confuse the consumer‟s awareness of the “source,
sponsorship, approval or certification of goods or services” or that
“represent that goods or services have sponsorship, approval,
characteristics, ingredients, uses, benefits or quantities that they do not

88. Robertson, supra note 1, at 224–25. This practice is especially common with DTC genetic
test providers who do business through the Internet. Id. The use of the Internet also enables third
party DTC genetic test companies to sell genetic tests that are supposed to be only clinically
available directly to consumers. Stuart Hogarth et al., Direct-to-Consumer Genetic Testing: Legal,
Ethical, and Policy Issues, 9 ANN. REV. GENOMICS & HUMAN GENETICS 161, 164 (2008)
(explaining that although Myriad Genetics does not sell its tests directly to patients, consumers are
able to purchase the tests from DNA Direct, a third party DTC genetic test company that uses its
own healthcare providers to order the test from Myriad).
89. Robertson, supra note 1, at 225. See also Turna Ray, CDC Advises Docs to Inform
Patients of Limitations of DTC Gene Scans, PHARMACOGENOMICS REP., July 29, 2010,
http://www.genomeweb.com/dxpgx/cdc-advises-docs-inform-patients-limitations-dtc-gene-scans
(explaining that even though some DTC companies have partnered with “wellness groups and
doctors,” the CDC believes that the tests are “lacking in terms of clinical validity and clinical
utility.”).
90. See Pollack, supra note 73. As the former director of the Genetics and Public Policy
Center at Johns Hopkins University said “„some doc on the payroll at Genes R Us‟ is not the same
as a personal physician.” Id. “A physician working for a company selling the [DTC genetic] tests
is clearly not well situated to look after a patient‟s best interest” when providing advice about the
need for the test or when ordering the test. David Magnus et al., Direct-to-Consumer Genetic
Tests: Beyond Medical Regulation?, 1 GENOME MED. 17 (2009), available at
http://genomemedicine.com/content/1/2/17.
91. GENETICS & PUB. POL‟Y CTR., SURVEY OF STATE FALSE ADVERTISING LAWS 1 (August
2009)
[hereinafter
FALSE
ADVERTISING
SURVEY],
available
at
http://www.dnapolicy.org/resources/Prince_StateFalseAdvertisingLaws.pdf.
92. Alan S. Brown & Larry E. Hepler, Comparison of Consumer Fraud Statutes Across the
Fifty States, 55 FDCC Q. 263, 263 (2005).
93. FALSE ADVERTISING SURVEY, supra note 91, at 1.
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have . . . .”94 Only two state statutes specifically address scientific and
clinical advertising claims.95 California‟s statute prohibits false and
misleading advertising claims that “purport to be based on . . . clinical
evidence.”96 Nevada‟s statute states that
a person engages in a „deceptive trade practice‟ when . . .
he or she makes an assertion of scientific, clinical or
quantifiable fact in an advertisement which would cause a
reasonable person to believe that the assertion is true,
unless, at the time the assertion is made, the person making
it has possession of factually objective scientific, clinical or
quantifiable evidence which substantiates the assertion[.]97
Furthermore, California‟s statute is the only one to specify that the
provisions apply to advertisements over the Internet, in addition to those in
more traditional publications.98 Despite broad trade practice laws that
provide states with another way to protect consumers, only one attorney
general has initiated an investigation into the claims made in DTC genetic
test advertisements.99
During the past decade, the number of states that allow some form of
DTC testing has increased.100 Individual states have the authority to strictly
regulate genetic tests,101 however, the majority of current state regulations
do not address the major concerns about test accuracy or appropriate
counseling for individuals who undergo genetic testing.102 The enforcement
94. DEL. CODE ANN. tit. 6, § 2532 (2005); GA. CODE ANN. § 10-1-372 (2009); ME. REV.
STAT. ANN. tit. 10, § 1212 (2009). Many states, including Alabama, Alaska, Colorado, Delaware,
Georgia, Hawaii, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Michigan, Minnesota,
Mississippi, Nebraska, New Hampshire, Oregon, Pennsylvania, Tennessee, Texas, Utah, and West
Virginia, have adopted provisions based on the Uniform Deceptive Trade Practices Act or
Uniform Consumer Sales Practices Act, and therefore have almost identical language in their state
statutes. Brown & Hepler, supra note 92, at 266–68, 290–308 (2005). See also FALSE
ADVERTISING SURVEY, supra note 91, at 1–32 (highlighting the applicable text in each state‟s
statute).
95. FALSE ADVERTISING SURVEY, supra note 91, at 1.
96. CAL. BUS. & PROF. CODE § 17508 (2008).
97. NEV. REV. STAT. ANN. § 598.0925 (2010).
98. CAL. BUS. & PROF. CODE § 17500 (2008).
99. FALSE ADVERTISING SURVEY, supra note 91, at 1; Andrew Pollack, A Genetic Test That
Very Few Need, Marketed to the Masses, N.Y. TIMES, Sept. 11, 2007,
http://www.nytimes.com/2007/09/11/business/media/11genetics.html.
100. Matthew Schulze, 25 Percent More States Allow Direct Access Testing, 32 LAB. MED.
661, 661 (2001). In 1999, twenty-seven states allowed consumers direct access to testing; by
2001, thirty-four states allowed direct access testing. Id. Thirty-seven states currently allow some
form of direct-to-consumer testing. DTC STATUTE SURVEY, supra note 77.
101. See U.S. CONST. amend. X (reserving any powers not delegated to the Federal
Government in the Constitution for the States). The regulation of health and safety matters is
generally reserved for State consideration. Javitt et al., supra note 30, at 273.
102. See supra text accompanying notes 62–72.
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of state regulation is also challenging because the majority of DTC genetic
tests are offered to consumers through the Internet, and the companies that
offer these tests may be outside the jurisdiction of any one state.103
Additionally, many states have followed the precedent set by various
federal agencies,104 and have not implemented specific regulations for DTC
genetic tests.105
B. Federal Regulation
Three federal agencies have the greatest potential ability to regulate
the DTC genetic tests currently available to consumers.106 The Food &
Drug Administration (FDA) has authority to regulate medical devices used
“in the diagnosis of disease or other conditions.”107 The Federal Trade
Commission (FTC) has a statutory mandate to protect consumers and to
prevent unfair or deceptive acts and practices, including false or misleading
advertising.108 The Centers for Medicaid and Medicare Services (CMS)
have authority to regulate medical testing within clinical laboratories under
the Clinical Laboratories Improvement Amendments of 1988 (CLIA).109
The regulatory authority of each agency is dependent on how each
particular genetic test is produced, marketed, performed, and interpreted.110
1. FDA Regulation
In 2000, an official government advisory committee recommended
that the “FDA should be the federal agency responsible for the review,
approval, and labeling of all new genetic tests.”111 This committee also
suggested that the FDA develop a review process that focuses on evaluating
genetic test analytical and clinical validity, as well as evaluating clinical
103. Javitt & Hudson, supra note 13, at 64. See generally James R. Pielemeier, Why General
Personal Jurisdiction Over “Virtual Stores” is a Bad Idea, 27 QUINNIPIAC L. REV. 625, 626
(2009) (explaining that courts have begun to address whether a website can be sufficient contact
for a state to assert jurisdiction). Although the D.C. Circuit and Ninth Circuit have found that an
accessible website can create general jurisdiction, the Fourth, Fifth, Sixth, Tenth, and Federal
Circuits have not found general jurisdiction in these cases. Id. at 626–27.
104. See discussion infra Part I.B.
105. See supra notes 77–87, 91–98 and accompanying text.
106. See Javitt et al., supra note 30, at 268 (introducing current federal regulation of genetic
tests); Novick, supra note 11, at 624–30 (discussing the current regulatory structure).
107. 21 U.S.C. § 321(h)(2) (2006).
108. 15 U.S.C. §§ 45(a)(1)–(2) (2006).
109. Clinical Laboratory Improvement Amendments of 1988, Pub. L. No. 100-578, 102 Stat.
2903 (1988) (codified at 42 U.S.C. § 263a).
110. Robertson, supra note 1, at 221.
111. SEC‟Y‟S ADVISORY COMM. ON GENETIC TESTING, NAT‟L INSTS. OF HEALTH,
ENHANCING THE OVERSIGHT OF GENETIC TESTS: RECOMMENDATIONS OF THE SACGT 27 (2000),
available at http://oba.od.nih.gov/oba/sacgt/reports/oversight_report.pdf.
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utility claims made by the test developers.112 The Federal Food, Drug, and
Cosmetic Act (FDCA) of 1938113 and the Medical Device Amendments of
1976114 give authority to the FDA to regulate medical devices. A medical
device is defined as “an instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar or related article,
including any component, part, or accessory, which is . . . intended for use
in the diagnosis of disease or other conditions, or in the cure, mitigation,
treatment, or prevention of disease . . . .”115
The FDA utilizes three categories of medical devices to determine how
much control is needed to ensure the safety and effective use of each
device.116 Class I devices are subject to the least FDA regulation oversight
and may be introduced directly into U.S. commerce.117 Class II devices
have an increased safety risk and are subject to greater FDA controls
including post-marketing surveillance and device performance standards to
ensure safety and effectiveness.118 Class III devices are defined as those: 1)
for which general controls and special control would not provide reasonable
assurance of safety and effectiveness; and 2) which are either for (a)
supporting, sustaining, or preventing impairment of human health, or (b)
present a potential unreasonable risk of illness of injury.119 Only a small
number of predictive medical tests are classified and regulated as Class III
medical devices; predictive personal genetic tests are generally not
considered Class III devices.120
Though the definition of a medical device provides the FDA broad
authority to regulate genetic tests, the FDA has chosen to limit its regulation

112. Id.
113. 21 U.S.C. §§ 301–399 (2006).
114. Pub. L. No. 94-295, 90 Stat. 539 (1976) (codified in scattered sections of 21 U.S.C.).
115. 21 U.S.C. § 321(h)(2) (2006). The FDA has previously considered only some genetic tests
in vitro diagnostic products. See Garcia, supra note 56, at 218 (explaining that the FDA considers
certain complex genetic tests In Vitro Diagnostic Multivariate Index Assays (IVDMIA)).
However, the FDA has recently decided to consider broader regulations for all laboratorydeveloped genetic tests, instead of focusing on IVDMIAs. Oversight of Laboratory Developed
Tests; Public Meeting; Request for Comments, 75 Fed. Reg. 34,463 (June 17, 2010); Turna Ray,
FDA Shelves IVDMIA Final Guidelines in Order to Focus on Overall LDT Regulation,
PHARMACOGENOMICS REP., June 17, 2010, http://www.genomeweb.com/dxpgx/fda-shelvesivdmia-final-guidelines-order-focus-overall-ldt-regulation.
116. Neil A. Holtzman, FDA and the Regulation of Genetic Tests, 41 JURIMETRICS 53, 59
(2000).
117. 21 U.S.C. § 360c(a)(1)(A) (2006).
118. § 360c(a)(B).
119. § 360c(a)(C).
120. Bruce Patsner, New “Home Brew” Predictive Genetic Tests Present Significant
Regulatory Problems, 9 HOUS. J. HEALTH L. & POL‟Y 237, 247 (2009). HIV tests are one of the
few predictive medical tests regulated as Class III medical devices. Id.
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of genetic tests.121 The limited regulation of new genetic tests may be due
to the availability of the FDA‟s pre-market notification process.122 The premarket notification process, also known as 510(k) abbreviated marketing
clearance, requires that developers “demonstrate that their new test is
substantially equivalent to a medical device currently on the market.” 123 If
the genetic test developer can produce data that demonstrates that a new test
is substantially equivalent to a test already available on the market, the new
test can be marketed in the same class as that test, and the developer does
not need to prove the new test‟s safety and effectiveness in order to gain
pre-market approval.124
The limited regulation of genetic tests may also be attributed to the
FDA regulatory distinction between genetic “home brew” tests, which are
developed and analyzed completely within one laboratory, and genetic tests
that contain components that travel in interstate commerce.125 The FDA has
chosen to regulate only the individual components and reagents used in the
genetic tests, and has declined to regulate genetic “home brew” tests or the
laboratories that develop and analyze them.126 Consequently, “home brew”
tests are classified as Class I or II medical devices that are subject to less
regulation than other genetic tests.127 Practically, this allows certain genetic
tests to reach the consumer market without any FDA evaluation for safety,
effectiveness, or accuracy.128 Consumers who purchase these DTC genetic
tests “are likely unaware that the FDA is not involved in [any] quality
manufacturing control or efficacy testing” of the products.129
In addition to the self-imposed regulatory distinctions created by
individual test development and components, the FDA has stated that its
regulatory power over medical devices cannot be extended to regulate
genetic tests marketed as services.130 This allows companies that market

121. See Robertson, supra note 1, at 223–24 (explaining that the FDA exercises “enforcement
discretion” in the regulation of certain genetic tests).
122. See Solberg, supra note 58, at 730 (introducing the pre-market notification process).
123. Id. New Class III medical devices may be introduced to consumers through an
abbreviated marketing application if the device is substantially equivalent to a device marketed
prior to May 28, 1976, or to devices classified as class I or II since that date. Patsner, supra note
120, at 246.
124. Holtzman, supra note 116, at 60.
125. Novick, supra note 11, at 629.
126. Patsner, supra note 120, at 251–52. See also Classification and Reclassification of
Restricted Devices, Analyte Specific Reagents, 62 Fed. Reg. 62,243, 62,245 (Nov. 21, 1997)
(discussing the FDA‟s intention not to regulate the reagents used in genetic tests differently from
other class I medical devices).
127. Patsner, supra note 120, at 249.
128. Id. at 254.
129. Id. at 249–50.
130. Robertson, supra note 1, at 61.
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their “home brew” tests as services to circumvent the entire FDA premarket approval process.131
In addition to the market approval regulations, genetic tests may be
subject to FDA regulations regarding medical device labeling.132 Genetic
tests that include FDA regulated components must comply with the
promulgated regulations regarding general medical device labeling,133 as
well as with regulations for in vitro diagnostic products.134 The FDA is
responsible for the regulation of advertising for restricted medical devices,
however genetic tests that are classified as Class I or II medical devices are
not considered restricted medical devices.135 DTC genetic tests and “home
brew” test kits are generally not subject to these regulations, so the labels
and materials included with these tests may include information that has not
been substantiated.136
2. FTC Regulation
The FTC may have a better ability to regulate the advertising of
genetic tests because the FTC has statutory authority to regulate the
advertising of most medical devices.137 The FTC also has a statutory
mandate to protect consumers and to prevent unfair practices and deceptive
acts.138 The FTC considers three factors in determining if a practice is
unfair: “1) whether the practice injures consumers; 2) whether it violates
established public policy; and 3) whether it is unethical and
unscrupulous.”139 An act is considered deceptive “if there is a
misrepresentation, omission, or other practice, that misleads the consumer
131. Patsner, supra note 120, at 254.
132. Solberg, supra note 58, at 728.
133. 21 C.F.R. § 801 (2009).
134. 21 C.F.R. § 809.10 (2009). For example, the FDA requires that some genetic tests “state
that their „[a]nalytic and performance characteristics are not established‟ . . . because they are „not
clinically validated.‟” Jennifer E. Spreng, The Food and Drug Administration and the Pharmacy
Profession: Partners to Ensure the Safety and Efficacy of the Pharmacogenomic Therapy, 13 J.
HEALTH CARE L. & POL‟Y 77, 91–92 (2010). The result reports generated from these tests are also
required to include a notification that the test is not cleared or approved by the FDA. Id. at 92.
135. See FDA Oversight of Direct-to-Consumer Advertising of Medical Devices: Hearing
Before the S. Special Comm. on Aging, 110th Cong. (2008) [hereinafter FDA Oversight]
(statement of Daniel Schultz, Director, Center for Devices and Radiological Health, Food & Drug
Administration), available at http://www.fda.gov/NewsEvents/Testimony/ucm096272.htm
(explaining that “few Class I and Class II devices are restricted by regulation”).
136. Solberg, supra note 58, at 729.
137. 15 U.S.C. §§ 52–55 (2006). See also FDA Oversight, supra note 135 (explaining that the
FDA has authority to regulate restricted medical devices and the FTC has authority to regulate
non-restricted medical devices).
138. 15 U.S.C. § 45(a)(1) (2006 & Supp. 2009).
139. FED. TRADE COMM‟N, FTC POLICY STATEMENT ON UNFAIRNESS (1980), available at
http://www.ftc.gov/bcp/policystmt/ad-unfair.htm.
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acting reasonably in the circumstances, to the consumer‟s detriment.”140
The FTC is also primarily responsible for the regulation of Internet-based
product advertising.141 FTC regulation is based on the content of the
advertisement or speech.142
Although the FTC has regularly taken action against a variety of health
product manufacturers, the agency has not yet exercised this authority
against any genetic test advertisement.143 This limited FTC action may be
directly related to the FDA‟s limited regulation of DTC genetic tests as
medical devices because the FTC often looks to the FDA‟s labeling
requirements to determine if a particular test claim is false or misleading.144
However, since the FDA has limited its regulation of genetic tests, the
majority of such tests are made available to consumers without any need for
efficacy validation.145 This affects the FTC‟s actions for claims about
genetic test advertisements because, without a FDA standard, the FTC may
not be able to clearly determine which DTC genetic test advertisements are
false or misleading.146 Without an FDA standard, FTC action against DTC
genetic test advertisements may also face increased First Amendment
scrutiny because there is little basis for the clear determination that the
claims are false or misleading.147
3. CLIA and CMS Regulation
CLIA148 establishes regulations to ensure that every laboratory
determines the analytical validity of its laboratory tests before offering them
for clinical purposes, such as use for disease diagnosis, prevention, or
treatment.149 Although CLIA was enacted to certify valid and reliable
medical testing, CLIA does not authorize or certify the validity of the
individual tests.150

140. FED. TRADE COMM‟N, FTC POLICY STATEMENT ON DECEPTION (1983) [hereinafter FTC
STATEMENT ON DECEPTION], available at http://www.ftc.gov/bcp/policystmt/ad-decept.htm.
141. Javitt & Hudson, supra note 13, at 65.
142. Javitt et al., supra note 30, at 286.
143. Javitt & Hudson, supra note 13, at 65.
144. Id.
145. Patsner, supra note 120, at 249–50.
146. Javitt & Hudson, supra note 13, at 65.
147. Id.
148. Clinical Laboratory Improvement Amendments of 1988, Pub. L. No. 100-578, 102 Stat.
2903 (1988) (codified at 42 U.S.C. § 263a).
149. LABORATORY PRACTICES, supra note 2, at 3; Holtzman, supra note 116, at 57. For
genetic tests, analytical validity refers to accurate identification of a particular genetic mutation.
Javitt & Hudson, supra note 13, at 59.
150. Robertson, supra note 1, at 222.

WEBSITE final(2)

S 18

4/18/2011 12:02 PM

JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 14: Supp.

CLIA imposes basic requirements for laboratory methodology and
documentation and standards for personnel qualification in order for a
laboratory to receive certification.151 CLIA certification also requires
periodic facility inspections and the examination of proficiency sample tests
for high complexity tests.152 Although genetic tests are highly complex and
require precise skill to perform and interpret, CMS does not require
laboratories that perform genetic testing to undergo specific proficiency
examinations for the genetic tests.153 In addition, although laboratories that
perform genetic tests must meet some personnel requirements to fulfill the
certification requirements for high-complexity testing, the actual
laboratories are still only subject to the general CLIA methodology and
documentation requirements.154 Furthermore, CLIA “does not require [that]
laboratories address the clinical validity or utility of tests [performed].”155
This is particularly problematic for “home brew” genetic tests because
CLIA does not include explicit authorization or a process for evaluating test
accuracy.156
Although CLIA requires that laboratories report any changes about
offered examinations and procedures to the Secretary of Health and Human
Services,157 CLIA does not authorize CMS to limit or restrict the offering
of a particular test.158 The decision to offer new genetic tests is left to the
discretion of each individual laboratory.159
The Centers for Disease Control and Prevention (CDC) advises CMS
on CLIA implementation, provides scientific and technical support for
CMS, and sponsors the Evaluation of Genomic Applications in Practice and
Prevention (EGAPP) program.160 Recently, the CDC published new
151. 42 U.S.C. §§ 263a(d)(1), (e)(2)(D), (f)(1) (2006).
152. §§ 263a(d)(3), (f)(3)(A); Javitt & Hudson, supra note 13, at 59. This distinction means
that “there are no specified quality control, personnel, or proficiency testing requirements
mandated under the CLIA regulations for most genetic tests.” At Home DNA Tests: Marketing
Scam or Medical Breakthrough: Hearing Before the S. Special Comm. on Aging, 109th Cong. 35–
36 (2006) (prepared statement of Kathy Hudson, Director, Genetics & Public Policy Center, and
Associate Professor, Berman Bioethics Institute, Institute of Genetic Medicine and Department of
Pediatrics, Johns Hopkins University).
153. Javitt & Hudson, supra note 13, at 59–61.
154. 42 C.F.R. § 493.1495 (2009); LABORATORY PRACTICES, supra note 2, at 3.
155. Holtzman, supra note 116, at 57. Clinical validity refers to whether the information
provided is relevant to an individual‟s health and disease. Javitt & Hudson, supra note 13, at 59.
Clinical utility refers to “the likelihood that use of a test will lead to an individual‟s improved
health outcome.” Id. at 61.
156. Javitt & Hudson, supra note 13, at 61.
157. 42 U.S.C. § 263a(d)(2)(B) (2006).
158. Javitt & Hudson, supra note 13, at 61.
159. Id.
160. GENETICS & PUB. POL‟Y CTR., WHO REGULATES GENETIC TESTS? (Feb. 27, 2006,
updated May 30, 2008), available at
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recommendations for good laboratory practices for ensuring the quality of
genetic testing.161 These recommendations address issues that develop
throughout the entire genetic testing process and include guidelines for
providing information and informed consent to users of the laboratory
services, specimen submission and handling, test referrals, quality control
procedures, proficiency testing, test reporting, and specimen and record
retention.162
In addition to advising CMS on the implementation of CLIA, the
CDC, through the Human Genome Epidemiology Network (Network), may
have the ability to determine the validity of genetic tests.163 By compiling
anonymous samples and data on genetic test results, the Network could
establish the frequencies of genotypes implicated in a variety of diseases to
determine more reliable estimates of test validity.164
II. HIV: A PAST EXAMPLE OF HOME TEST KIT CONTROVERSY
Los Angeles public health officials reported the first cases of acquired
immunodeficiency syndrome (AIDS) in 1981.165 By 1987, the CDC
determined that the human immunodeficiency virus (HIV) caused AIDS,
and that the disease was spread through exposure to infected blood.166 The
CDC, in conjunction with state and local health departments, began a
national public education campaign to combat the spread of the HIV and
AIDS.167 Initial guidelines suggested that “[c]ounseling and testing persons

http://www.dnapolicy.org/policy.issue.php?action=detail&issuebrief_id=10. The EGAPP program
makes non-binding recommendations about the validity and utility of specific genetic tests based
on systematic, evidence-based genetic test assessments. Id.
161. LABORATORY PRACTICES, supra note 2, at 1.
162. Id. at 7.
163. Holtzman, supra note 116, at 57.
164. Id. at 57–58.
165. Michael S. Gottlieb et al., Pneumocystis Pneumonia – Los Angeles, 30 MORBIDITY &
MORTALITY
WKLY.
REP.
250
(1981),
available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm. This report described the cases of a
rare pneumonia in five previously healthy homosexual men. Id. at 250–51. The accompanying
editorial note suggested that the disease was “related to a common exposure” and “acquired
through sexual contact.” Id. at 251.
166. Ctrs. for Disease Control & Prevention, Dep‟t of Health & Human Servs., Perspectives in
Disease Prevention and Health Promotion Public Health Service Guidelines for Counseling and
Antibody Testing to Prevent HIV Infection and AIDS, 36 MORBIDITY & MORTALITY WKLY. REP.
509,
509
(1987)
[hereinafter
Perspectives],
available
at
http://www.cdc.gov/mmwr/preview/mmwrhtml/00015088.htm.
167. Ctrs. for Disease Control & Prevention, Dep‟t of Health & Human Servs., HIV and AIDS
– United States, 1981-2000, 50 MORBIDITY & MORTALITY WKLY. REP. 430, 433 (2001),
available at http://www.cdc.gov/mmwr/PDF/wk/mm5021.pdf.
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who are infected or at risk for acquiring HIV infection is an important
component of prevention strategy.”168
A. Debated Development of the Home Test Kit
In 1986 and 1987, the FDA reviewed several applications for the
manufacture of a HIV home test kit.169 The FDA found that the proposed
kits were medical devices subject to regulation under the FDCA and
determined that the kits were not eligible for 510(k) abbreviated marketing
clearance.170 In 1988, the FDA decided to limit the marketing of HIV
testing blood collection kits to those kits intended for professional use,171
which effectively banned the development of a HIV home test kit.172 Critics
of the home testing kits included the American Medical Association, the
CDC, several congressmen, and many gay activists.173 These objectors
argued that the home tests would produce inaccurate results, increase the
risk of suicide, and minimize the importance of pre- and post-test
counseling.174
Though the ban continued for a number of years, in 1994 the FDA
announced plans to reconsider the approval of HIV home test kits.175 This
announcement indicated that the FDA might be receptive to the use of
home HIV tests.176 Once again, the debate between objectors and advocates
of the HIV home test focused on concerns for users‟ welfare and their
understanding of the test process and results. Objectors to the home test
challenged the accuracy of the tests and raised concerns about the potential
harms that home testers would suffer without face-to-face pre- and post-test
counseling.177 Because a key aspect of the HIV home test kit was the
availability of anonymous testing, objectors also raised concerns about the

168. Perspectives, supra note 166, at 509.
169. Home Test Kits Designed to Detect HIV-1 Antibody, 54 Fed. Reg. 7279, 7280 (Feb. 17,
1989). The proposed kits were to include instructions and equipment for sample collection,
packaging materials for shipment to a laboratory for testing, and a confidential mechanism to
receive the test results. Id.
170. Id. See also supra notes 122–24 and accompanying text (discussing the 510(k)
abbreviated marketing clearance process).
171. Home Test Kits Designed to Detect HIV-1 Antibody, 54 Fed. Reg. at 7280.
172. Steven R. Salbu, HIV Home Testing and the FDA: The Case for Regulatory Restraint, 46
HASTINGS L.J. 403, 403 (1995).
173. Alexi A. Wright & Ingrid T. Katz, Home Testing for HIV, 354 NEW ENG. J. MED. 437,
438 (2006).
174. Bayer et al., supra note 19, at 1296–97; Wright & Katz, supra note 173, at 438.
175. Food and Drug Administration Advisory Committee Meeting; Amendment of Notice, 59
Fed. Reg. 29,814, 29,814 (June 9, 1994).
176. Id.; Salbu, supra note 172, at 403–04.
177. See Bayer et al., supra note 19, at 1296–97 (raising a number of questions about use of the
home test kit).
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impact that home HIV testing would have on public health practices and
policies that mandated the reporting of HIV infection to local and state
registries.178 In contrast, supporters of the HIV home test argued that the
availability of a home test would increase the number of people tested for
HIV infection, which would lead to reductions in risk behaviors and curb
the spread of HIV.179
1. Test Accuracy Concerns
On both occasions when the FDA considered the approval of a HIV
home test, the safety and efficacy of the home test kit was one of the most
contested issues.180 Opponents to home testing focused on the fact that
society generally needs medical professionals because patients are unable to
diagnose or treat themselves;181 the HIV home test raised concerns because
it required patients to collect their own specimens for testing.182 The use of
individual patient specimen collection also raised concerns about the
effectiveness of the home test kits when compared to test products
developed for clinical professional use.183 Objectors speculated that nonprofessional individuals utilizing the test would compromise test accuracy
through contamination or misuse.184 There was also concern that users
would not use the kits in a timely manner so the test kits would expire or
become outdated through the inability to register new viral mutations
discovered as testing technology continued to develop.185
2. Pre- and Post-Test Counseling and Treatment Concerns
In addition to concerns about the safety and efficacy of the testing
process, multiple concerns were raised about the need for individuals
participating in HIV testing to receive appropriate pre- and post-test

178. Id. at 1298. See also William O. Fabbri, Note, Home HIV Testing and Conflict with State
HIV Testing Regulations, 21 AM. J.L. & MED. 419, 419 (1995) (discussing approval of a home
HIV test and various state HIV testing laws).
179. Fabbri, supra note 178, at 421–22; Kathryn A. Phillips et al., Potential Use of Home HIV
Testing, 332 NEW ENG. J. MED. 1308, 1308 (1995). Researchers found that black and Hispanic
respondents, people with potentially less access to health care and HIV testing, and people with
less education and lower incomes were more likely to say that they would use home HIV tests. Id.
at 1308–09. The researchers determined that this was a significant finding because “preventive
services and other home tests are usually more likely to be used by people with higher incomes
and more education.” Id. at 1309.
180. Salbu, supra note 172, at 413.
181. Id. at 412.
182. Bayer et al., supra note 19, at 1296; Salbu, supra note 172, at 412.
183. Salbu, supra note 172, at 415.
184. Fabbri, supra note 178, at 429.
185. Id.; Salbu, supra note 172, at 415.
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counseling and treatment.186 Objectors worried that individuals who
received a positive test result over the phone would be unable to handle the
“death sentence.”187 There was also concern that individuals who received
their test results over the phone would hang up before receiving necessary
counseling.188 The objectors argued that the mandatory face-to-face preand post-test counseling that individuals received while getting clinical HIV
testing was essential.189 Supporters of the HIV home test argued that the
level of face-to-face counseling available at clinical offices and HIV-testing
facilities was variable, and that some HIV-testing clinics provided little or
no counseling at all.190 Supporters asserted that specialized HIV counselors
would have the opportunity to provide a consistent level of counseling to
those receiving positive results over the telephone.191 The supporters relied
on the success of other telephone counseling services including suicide hot
lines and already established AIDS hot lines.192 Furthermore, supporters of
home testing maintained that certain individuals would prefer to deal with
an anonymous counselor over the phone instead of face-to-face
counseling.193
B. An Approved Home Test Kit
Despite the concerns raised by opponents and advocates, the FDA
eventually approved the Home Access HIV-1 Test System on July 22,
1996.194 This home test kit is intended for anonymous, self-use HIV testing
186. See generally Salbu, supra note 172, at 417–26 (grouping these concerns into four
categories).
187. Fabbri, supra note 178, at 422–23. Some AIDS activists reinforced this concern by
referencing the obituary of a man who had jumped off of the Golden Gate Bridge after learning
that he was HIV-positive. Wright & Katz, supra note 173, at 438.
188. Fabbri, supra note 178, at 423. One of the greatest issues raised concerning individuals
who would possibly not receive adequate counseling was the fact that the user would have a lack
of knowledge regarding the possibility of false positive results. Id.
189. See Salbu, supra note 172, at 421–23 (outlining and responding to arguments that inperson counseling is a necessary part of an effective HIV testing program).
190. Id. at 419–20.
191. Id. at 423–24.
192. Fabbri, supra note 178, at 424.
193. Id. This position was supported by evidence that a significant number of individuals who
underwent HIV tests in a clinical setting did not return for their test results or counseling. Id. See
also Barnard M. Branson, Home Sample Collection Tests for HIV Infection, 280 JAMA 1699,
1701 (1998). Following the approval of the HIV home test kits, researchers determined that 97%
of users called for results, whereas the average return rate of individuals to clinical settings for
results was 67% in 1996, with a 51% chance of return to sexually transmitted disease clinics. Id.
194. Letter from Dr. Jay S. Epstein, Director, Office of Blood Research and Review, Ctr. for
Biological Evaluation and Research, U.S. Food & Drug Admin., to Michael Wandell, Home
Access
Health
Corp.
(July
22,
1996),
available
at
http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/Premarket
ApprovalsPMAs/ucm091848.htm; U.S. Food & Drug Admin., Home Access HIV-1 Test System
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by adults.195 The test kit requires that each user call a toll-free telephone
number to register their unique eleven-digit code.196 During this phone call,
the user “is asked to provide basic demographic data, . . . a history of prior
HIV antibody testing, knowledge of prior test results, expected result from
the current test, and risk factors for HIV infection.”197 After answering
these questions, the user “listens to an automated, 5-minute educational
session about the HIV-1 antibody test, HIV prevention, risk reduction
behavior, and AIDS.”198 This registration process is available to the test
user at any time, 24 hours a day, seven days a week.199 During this
registration process, the user also has the option of speaking with a
counselor or physician to discuss any questions or concerns.200
After collecting their own blood specimens, users ship their samples to
the Home Access Lab.201 Once the specimen reaches the lab, the blood
sample is tested by “experienced technicians using the exact same test
ordered by doctors‟ offices, hospitals and clinics, ensuring greater than
99.9% accuracy.”202 Users retrieve their test results by calling a toll-free
number and providing their unique eleven-digit code.203 The company
states that “[a]ll clients with indeterminate or positive results receive the
test results directly from a counselor.”204 In addition, a predetermined
Summary of Safety and Effectiveness 1 (1996) [hereinafter Test System], available at
http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/
PremarketApprovalsPMAs/ucm091849.pdf. The FDA also approved another home HIV test
manufactured by Direct Access Diagnostics in 1996, however the company withdrew its product
from the market due to “lack of demand.” Branson, supra note 193, at 1699.
195. Test System, supra note 194, at 1. Each kit includes: an instruction manual, an HIV/AIDS
educational booklet in English and Spanish, two safety lancets, an alcohol wipe, a sterile gauze
pad, a bandage, a safety lancet disposal container, a blood spot collection card pre-coded with a
unique eleven-digit number, a foil return pouch containing a desiccant, a shipping container, and a
pre-addressed, prepaid return envelope. Id.
196. Id. at 2. The Direct Access Diagnostics test did not require a registration phone call and
instead used a pamphlet included with the test kit to provide pre-test counseling information.
Branson, supra note 193, at 1699.
197. Test System, supra note 194, at 2. Users are asked to provide their year of birth, sex, race,
and zip code. Id.
198. Id.
199. The
Home
Access®
HIV-1
Test
System,
HOME ACCESS HEALTH,
http://www.homeaccess.com/HIV_RegisterStep1.asp (last visited Mar. 18, 2011).
200. Id.; Test System, supra note 194, at 2.
201. The Home Access® Express HIV-1 Test How it Works, HOME ACCESS HEALTH,
http://www.homeaccess.com/ExpressHIV_How_Works.asp (last visited Mar. 18, 2011)
[hereinafter How it Works]. The laboratory is FDA approved, CLIA certified, and accredited by
the College of American Pathologists. Id.
202. Id.
203. Test System, supra note 194, at 2. Test results are available seven days after the user ships
the specimen to the laboratory, unless the user purchases an “Express” test kit, in which case the
results are available the next business day after shipping. How it Works, supra note 201.
204. Test System, supra note 194, at 3.
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percentage of clients with negative results also receive test results from a
counselor, while the remaining clients receive their negative test results
from an interactive voice response system.205 All clients, regardless of their
test results, are able to speak with counselors once their results become
available.206
As a counselor provides results to the home test user, he or she also
evaluates each test user‟s “coping skills, availability of personal support
networks, and ability to inform sexual/needle-sharing partners” of the test
results.207 Clients with positive results are referred to local physicians,
clinics, and public health services in order to facilitate notification and
treatment.208 Counselors may also provide referrals to the National AIDS
Hotline and other psychosocial services.209
III. FILLING IN THE REGULATORY CRACKS
The current patchwork system of DTC genetic test regulation does not
adequately protect consumers from potentially suspect genetic tests.210
Although health is generally considered an area of state regulation,211
continuing to rely on individual state DTC genetic test regulation will create
a further “patchwork of non-uniform requirements.”212 Furthermore, since
the majority of DTC genetic tests are offered to consumers through the
Internet, the companies that offer these tests may be outside the jurisdiction
of any one state, which may make state regulatory enforcement difficult.213
A more effective and comprehensive federal regulatory scheme is necessary
to ensure that genetic tests are appropriately used to improve individual
health.214
A. FDA
To improve the regulation of DTC genetic tests, the FDA should
follow the precedent set by the agency‟s decisions about the requirements
and regulation of home HIV test kits. The HIV home test is currently

205. Id.
206. Id. “Clients with negative results may speak with a counselor as often as three times in a
30 day period after their results become available. Clients with positive results may speak with a
counselor 6 times over 12 months after their results become available.” Id.
207. Id.
208. Id. at 3–4.
209. Id. at 4.
210. See supra text accompanying notes 11–15.
211. Javitt et al., supra note 30, at 273.
212. Javitt & Hudson, supra note 13, at 64.
213. Id.
214. Id. at 66.
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regulated by the FDA as a Class III medical device.215 Similar classification
of DTC genetic tests as Class III medical devices, in contrast to the current
regulation of genetic tests as either Class I or Class II medical devices,216
would be an appropriate way to ensure “that the FDA subjects [DTC
genetic] tests to sufficient oversight without unnecessary burden.”217
Though only a small number of predictive medical tests are currently
regulated as Class III medical devices, the FDA has previously determined
that HIV tests must undergo increased medical device regulation due to the
possibility of dramatic health-related decisions based on the HIV test
results.218 Genetic test results are used primarily for predictive purposes
and have equally great implications for dramatic health-related decisions,219
yet the FDA has limited regulation to certain tests and reagents.220 The
FDA should acknowledge that the concerns currently being raised about the
potentially dangerous use of DTC genetic test results are identical to the
concerns raised in the 1990s about the use of HIV home test kits.221
Concerns about an individual‟s use of DTC genetic test results without
appropriate counseling may be addressed by the FDA imposing a
counseling requirement, similar to that applied to HIV home test kits, for
any individual who wishes to receive his DTC genetic test results.222
Following the HIV home test example, DTC genetic test companies should
be required to provide consumers access to telephone counseling pre- and
post-genetic testing.223 The availability and use of pre- and post-test
telephone counseling will ensure that the individual consumers receive all
of the information necessary to make informed health decisions based on
their genetic test results.224
The availability of personalized telephone counseling may also help
individuals who are interested in genetic testing but are concerned about the

215. Patsner, supra note 120, at 247.
216. Id.
217. Solberg, supra note 58, at 736.
218. Patsner, supra note 120, at 247. See also supra note 187.
219. See supra text accompanying note 41–45 and note 69.
220. Robertson, supra note 1, at 223.
221. See discussion supra Part II.A.
222. See supra text accompanying notes 199, 203–208.
223. At least one DTC genetic test company has acknowledged the need to provide consumers
with greater counseling options. 23andMe Partner to Provide Genetic Counseling, GENOMEWEB
DAILY NEWS, June 7, 2010, http://www.genomeweb.com/dxpgx/23andme-partner-providegenetic-counseling.
224. The use of specially trained counselors to provide the genetic test results to consumers
over the phone may also address concerns that some physicians are insufficiently prepared to
interpret what genetic results mean for a particular patient. See Gniady, supra note 42, at 2448.
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confidentiality of their test results.225 The convenience and confidential
nature of home genetic testing is likely to attract additional consumers.226
Additional FDA regulation of DTC genetic tests will ensure that the genetic
tests provided to consumers who wish to avoid traditional health care
settings provide valid and useful results. Even though widespread use of
home genetic tests may be limited because the tests are home collection
kits,227 eventually home genetic testing may become as commonplace and
as accepted as home-use pregnancy testing.228
In order for home genetic testing to be utilized to its greatest potential,
the FDA must clarify or eliminate the regulatory distinction between “home
brew” genetic tests and genetic tests that contain components that travel in
interstate commerce.229 This distinction and the 510(k) clearance process
currently enable the majority of genetic tests to reach the consumer market
without any evaluation for safety, effectiveness, or accuracy.230
Reclassifying DTC genetic tests as Class III medical devices would
alleviate this problem because all Class III medical devices are subject to
the most stringent regulations.231 Furthermore, the classification of all DTC

225. See supra text accompanying notes 58–61. It is important to note that the information
provided to DTC genetic test companies may not be covered under HIPAA regulations because it
is unclear if DTC genetic test companies are considered health care providers. See Health
Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 110 Stat. 1936 (1996).
In addition, GINA regulations may not apply unless the DTC genetic test company provides the
consumer‟s genetic information to an employer or insurer. See Genetic Information
Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 881 (to be codified in scattered
sections of 26, 29, and 42 U.S.C.).
226. Solberg, supra note 58, at 714–15.
227. A home collection kit requires that the consumer collect a sample at home and send the
specimen to a laboratory for analysis. Salbu, supra note 172, at 416 n.65. The consumer does not
have the ability, equipment, or skill necessary to analyze or interpret the test results without the
assistance of a laboratory technician. The HIV home test and DTC genetic tests are both
considered home collection kits.
228. The traditional home pregnancy test is considered a home-use test kit because the
consumer is able to collect the specimen and interpret the test in the comfort of her own home.
Since 2006, one HIV test manufacturer has been seeking approval for an over-the-counter HIV
home-use test kit that will utilize saliva instead of blood. Wright & Katz, supra note 173, at 437–
39. This test “works like a home pregnancy test, except that it uses oral fluid instead of urine.” Id.
at 437. This test technology is currently used in clinical settings but has not been approved for
over-the-counter use. See id. at 439 (reporting use of the rapid tests in clinics).
229. See Novick, supra note 11, at 629.
230. Patsner, supra note 120, at 254. One could argue that genetic tests should not even be
eligible for 510(k) clearance due to the complexity of the tests and the lack of a pre-1976 predicate
device. However, this issue may soon be addressed because the FDA has recently released a plan
to revamp the 510(k) submission process. Matt Jones, UPDATE: FDA Plans Streamlining 510(k)
Process
in
2011,
GENOMEWEB
DAILY
NEWS,
Jan.
20,
2011,
http://www.genomeweb.com/dxpgx/update-fda-plans-streamlining-510k-process-2011.
231. See 21 U.S.C. § 360c(a) (2006) (setting out the requirements for all three classes of
medical devices).
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genetic tests as restricted Class III medical devices would subject these tests
to stricter FDA labeling requirements.232
B. FTC
The current FDA regulatory scheme that separates “home brew”
genetic tests from other DTC genetic tests limits the FTC‟s ability to pursue
claims against DTC genetic companies that use unfair or deceptive practices
in their advertisements.233 The FDA‟s different labeling requirements and
regulations negatively impact the viability of any currently proposed FTC
claim because there is no applicable standard to determine if a DTC genetic
test advertisement is misleading.234 In order for the FTC to successfully
pursue claims for deceptive acts and practices, the test company‟s
misrepresentation, omission, or practice must be material to the consumer‟s
decisions regarding the genetic test.235 Though claims and omissions
related to health and safety are generally considered presumptively
material,236 without a clear FDA standard, the FTC does not have an
incentive to use its limited resources on claims that do not appear to be
causing actual harm to a large number of people.237
More comprehensive and clearly defined FDA regulations will enable
the FTC to better embrace its statutory role and protect consumers from
misleading genetic test advertisements.238 The classification of DTC
genetic tests as Class III medical devices will impose standard regulations
for labeling239 and will allow the FTC to clearly determine which test
advertisements are false or misleading.240 Furthermore, a more clearly
defined standard will limit the success of any First Amendment protected
speech claims.241

232. See FDA Oversight, supra note 135 (explaining that the current FDA oversight of
“medical device advertising is limited to a subset of medical devices.”).
233. See discussion supra Part I.B.2.
234. Javitt & Hudson, supra note 13, at 65.
235. FTC STATEMENT ON DECEPTION, supra note 140.
236. Id.; Javitt et al., supra note 30, at 283.
237. See Javitt et al., supra note 30, at 286 (explaining that the FTC has historically reserved
its resources for cases where there is “a showing of concrete harm to consumers from the use
of . . . products as a result of claims made in advertising.”).
238. See supra Part I.B.2.
239. See FDA Oversight, supra note 135.
240. Javitt & Hudson, supra note 13, at 65.
241. Id.
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C. CLIA

To fully fill in the regulatory cracks, better coordination and
harmonization is also needed between CMS, the FDA, and the FTC.242
Although CLIA was enacted to ensure the analytical validity of laboratory
tests,243 the current regulations have limited effect because they only
address the validity of the testing process and not the validity of the
individual tests.244 Furthermore, the current CLIA regulations fail to
impose any obligation on the laboratories to explain to patients the meaning
of their test results or the limitations of specific tests.245 Though individual
genetic test validity may be best addressed by more comprehensive and
clearly defined FDA regulations, under CLIA the determination of
performance specifications for genetic tests that have not been cleared or
approved by the FDA will help ensure the clinical validity of these tests,
regardless of how the FDA classifies or regulates them.246 The
determination of clinical validity may also improve potential FTC action
because better quality control will lead to improved reports and will allow
the FTC to more clearly determine which test claims are false or
misleading.
The CDC should urge laboratories to apply and utilize the recently
published recommendations for good practices for ensuring the quality of
genetic testing. The implementation of proficiency testing for genetic tests
can help laboratories “reduce analytic deficiencies, improve testing
procedures, and take steps to prevent future errors.”247 Finally, the CDC
should consider utilizing the Human Genome Epidemiology Network to
establish more reliable estimates of validity based on genotype
frequencies.248
242. See generally Letter from Todd E. Gillenwater, Vice President, Pub. Policy, Cal.
Healthcare Inst., to U.S. Food & Drug Admin. (April 14, 2009), available at
http://www.regulations.gov/search/Regs/home.html#documentDetail?R=0900006480953351
(describing the different approaches and criteria currently considered under CLIA and by the FDA
for ensuring test safety and effectiveness). In June 2010, CMS and the FDA signed a
Memorandum of Understanding that acknowledged the need for greater collaboration between the
two agencies. CTRS. FOR MEDICARE & MEDICAID SERVS. & U.S. FOOD & DRUG ADMIN., MOU
225-10--0010, MEMORANDUM OF UNDERSTANDING BETWEEN UNITED STATES FOOD AND DRUG
ADMINISTRATION AND CENTERS FOR MEDICARE & MEDICAID SERVICES (2010), available at
http://www.fda.gov/aboutfda/partnershipscollaborations/memorandaofunderstandingmous/domest
icmous/ucm217585.htm. The agencies “agree[d] to work together to promote initiatives related to
the review and use of FDA-regulated . . . medical devices . . . .” Id.
243. LABORATORY PRACTICES, supra note 2, at 3.
244. Robertston, supra note 1, at 222.
245. Javitt et al., supra note 30, at 271 (explaining that there are no regulations regarding what
laboratories may say when promoting genetic tests.).
246. LABORATORY PRACTICES, supra note 2, at 12–14.
247. Id. at 5.
248. Holtzman, supra note 116, at 57. See also supra text accompanying note 164.
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IV. CONCLUSION
The unique nature of genetic information and the predictive purpose of
genetic test results distinguish genetic information and genetic testing from
other health information and diagnostic tests.249 Although genetic testing is
one of the fastest growing areas of laboratory testing,250 proper use of this
technology may be limited by the current patchwork regulatory scheme.251
The National Institutes of Health recently announced the creation of the
Genetic Testing Registry (GTR), a public database that will provide
increased access to information about the availability, validity, and
usefulness of genetic tests to researchers, consumers, health care providers,
and the public.252 The GTR is intended to be a comprehensive resource that
provides detailed information about genetic tests currently available to
patients; however, the information included in the GTR will be provided
voluntarily by the genetic test providers.253 Since the GTR is voluntary, it is
uncertain if the genetic testing companies will participate and provide
meaningful or useful information about their tests.254
Although the GTR is a step in the right direction,255 a better way to
ensure that researchers, consumers, health care providers, and the public
have access to accurate genetic tests that provide meaningful results is to fill
in the current regulatory cracks. The FDA‟s experience with home HIV
tests provides a viable path for implementing regulatory improvements.256
Revamped FDA regulations and improved coordination between the FDA,
FTC, and CMS will help ensure the quality of all genetic tests and will
provide patients and physicians with greater confidence in genetic testing.

249. Javitt et al., supra note 30, at 260.
250. LABORATORY PRACTICES, supra note 2, at 3.
251. Robertson, supra note 1, at 222.
252. Press Release, Nat‟l Insts. of Health, NIH Announces Genetic Testing Registry (March
18, 2010), available at http://www.nih.gov/news/health/mar2010/od-18.htm.
253. Id.
254. The disclosure of some information may also be hampered by the NIH‟s expectation that
the GTR will be used to “[f]acilitate genetic and genomic data-sharing for research and new
scientific discoveries.” Id.
255. Press Release, Genetics & Pub. Pol‟y Ctr., Center Applauds NIH‟s Newly Announced
Genetic Test Registry as an Important First Step (March 18, 2010), available at
http://www.dnapolicy.org/news.release.php?action=detail&pressrelease_id=138.
256. See discussion supra Part III.A.

